Newsbenzinga
Anixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian Cancer
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…